Gigacloud Technology Inc vs Moderna, Inc. — how do they compare? Gigacloud Technology Inc trades at $51.18 (market cap $1.84B), while Moderna, Inc. trades at $63.16 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 13.1× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| GCT | MRNA | |
|---|---|---|
Market Cap | $1.84B | $24.18B |
Sector | Technology | Health |
52-Week High | $53.25 | $81.80 |
52-Week Low | $25.44 | $22.36 |
Enterprise Value | $1.97B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $51.25, down 0.78% on the day, with strong technical momentum showing bullish moving averages and key resistance at $53. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.16 beating estimates by 29%, maintaining consistent earnings beats and 10.65% net margins. Revenue growth accelerated to 28% in Q2 2026, reaching $1.5B annually, while cash flow generation remains healthy at $120M net cash flow for 2025.
GCT presents a compelling growth story with attractive valuation at 12.25 P/E ratio and strong analyst support (67% buy ratings). Key risks include competitive pressures in furniture logistics and potential margin compression from expansion costs. The stock's technical overbought condition (RSI above 84) suggests near-term consolidation may precede further upside driven by execution on European expansion and New Classic integration.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →